PT  - JOURNAL ARTICLE
AU  - Yumiko Tsushima
AU  - M. Cecilia Lansang
AU  - Vinni Makin
TI  - The role of SGLT-2 inhibitors in managing type 2 diabetes
AID  - 10.3949/ccjm.88a.20088
DP  - 2021 Jan 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 47--58
VI  - 88
IP  - 1
4099  - http://www.ccjm.org/content/88/1/47.short
4100  - http://www.ccjm.org/content/88/1/47.full
SO  - Cleve Clin J Med2021 Jan 01; 88
AB  - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are an exceptionally versatile class of medication, and their glycemic and nonglycemic benefits could help millions of patients with type 2 diabetes. Of note, they have been shown to improve cardiac and renal outcomes, much-needed benefits in patients with type 2 diabetes, who are at a higher risk for developing cardiac and renal dysfunction than those who do not have diabetes. The indications for SGLT-2 inhibitors may continue to expand as ongoing clinical trials provide more insight into these drugs.